Compare Sana Biotechnology Inc (SANA) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vanguard Growth Index Fund ETF — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while Vanguard Growth Index Fund ETF trades at $88.89. The key difference: Vanguard Growth Index Fund ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | VUG | |
|---|---|---|
Market Cap | $1.13B | — |
Sector | Health | Sector/Thematic |
52-Week High | $5.92 | $90.29 |
52-Week Low | $2.68 | $70.00 |
Enterprise Value | $1.05B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
VUG trades at $88.94, down 0.27% on the day, with a bullish technical signal driven by moving averages. The ETF shows strong institutional accumulation, with multiple firms increasing holdings by over 500% in Q2 2026. RSI levels above 70 indicate potential overbought conditions, while support sits near $88 and resistance at $90.
The outlook remains positive given institutional confidence and growth ETF appeal, but high RSI suggests near-term consolidation risk. Investors face volatility from market sentiment shifts, though long-term growth exposure aligns with historical outperformance versus the S&P 500.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
